4D Molecular Therapeutics sold Asia‑Pacific rights to its retinal gene therapy 4D‑150 to Otsuka Pharmaceutical for $85 million up front plus potential cost‑sharing and up to $336 million in milestones. 4D‑150 encodes aflibercept with an anti‑VEGF‑C element to provide sustained anti‑VEGF activity and reduce injection burden; 4DMT reported phase‑2 60‑week data showing a 78% reduction in supplemental injections at the phase‑3 dose versus projected Eylea use. 4DMT will lead global phase‑3 and manufacturing activities while Otsuka supports APAC development and potential commercialization. Gene therapy here delivers a transgene for sustained intraocular expression rather than repeat intravitreal injections.